Trans-Atlantic M&A, a phenomenon that made up a significant portion of activity at the height of the last M&A boom, looks set to continue its post-millennium downward trajectory. Despite a couple of sizeable US life sciences takeovers by European companies in recent weeks, trans-Atlantic deal-making has been in a state of marked decline in the years since 2000. European corporates have largely shunned US assets and overall levels have been largely maintained by the appetite of US companies and private equity investors for European assets.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access